Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-7. (Canceled)

8. (Currently Amended) A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of: producing an AT_4 receptor ligand, having a structure selected from the group consisting of ~~with the structure~~ NH_3^+-norleucine-tyrosine-isoleucine-histidine-COO^-, and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-$CONH_2$; ~~or norleucine-tyrosine-leucine-[(CH2-HN2)3-4-histidine-proline-phenylalanine)-COO-~~; and administering the AT_4 receptor ligand.

9. (Currently Amended) The method of inhibiting angiogenesis ~~accordingly~~ according to claim 8 or claim 29, further comprising the delivery of the AT_4 receptor ligand locally.

10. (Currently Amended) The method of inhibiting angiogenesis according to claim 8 or claim 29 , further comprising the delivery of the AT_4 receptor ligand intravascularly.

11. (Currently Amended) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT_4 receptor ligand intramuscularly.

12. (Currently Amended) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT_4 receptor ligand intraperitoneally.

13. (Currently Amended) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT_4 receptor ligand subcutaneously.

14. (Currently Amended) The method of inhibiting angiogenesis according to claim 8 or claim 29, further comprising the delivery of the AT_4 receptor ligand orally.

15. (Currently Amended) A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of: producing an AT_4 receptor ligand, having a structure selected from the group consisting of: ~~with the structure~~ NH_3^+-norleucine-tyrosine-isoleucine-histidine-COO^-, and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-$CONH_2$; ~~or norleucine-tyrosine-leucine-Ψ-$(CH_2$-$HN_2)^{3-4}$-histidine-proline-phenylalanine)-COO^-~~ and administering the AT_4 receptor ligand.

16. (Currently Amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15 or claim 30, further comprising delivery of the AT_4 receptor ligand locally.

17. (Currently Amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15 or claim 30, further comprising the delivery of the AT_4 receptor ligand intravascularly.

18. (Currently Amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15 or claim 30, further comprising the delivery of the AT_4 receptor ligand intramuscularly.

19. (Currently Amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15 or claim 30, further comprising the delivery of the AT_4 receptor ligand intraperitoneally.

20. (Currently Amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15 or claim 30, further comprising the step of applying the AT_4 receptor ligand subcutaneously.

21. (Currently Amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15 or claim 30, further comprising the step of applying the AT_4 receptor ligand orally.

22. (Currently Amended) A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of: producing an AT_4 receptor ligand, having a structure selected from the group consisting of: ~~with the structure~~ NH_3^+-norleucine-tyrosine-isoleucine-histidine-COO^-, and norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-$CONH_2$; ~~or norleucine-tyrosine-leucine-Ψ-$(CH_2$-$HN_2)^{3-4}$-histidine-proline-phenylalanine)-COO^-~~; and administering the AT_4 receptor ligand.

23. (Currently Amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT_4 receptor ligand locally to the tumor.

24. (Currently Amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT_4 receptor ligand intravascularly.

25. (Currently Amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT_4 receptor ligand intramuscularly.

26. (Currently Amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT_4 receptor ligand intraperitoneally.

27. (Currently Amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT_4 receptor ligand subcutaneously.

28. (Currently Amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22 or claim 31, further comprising the delivery of the AT_4 receptor ligand orally.

29. (New) A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of: producing an AT_4 receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-$(CH_2\text{-}NH_2)^{3\text{-}4}$-histidine-proline-phenylalanine-COO^-; and administering the AT_4 receptor ligand.

30. (New) A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of: producing an AT_4 receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-$(CH_2\text{-}NH_2)^{3\text{-}4}$-histidine-proline-phenylalanine-COO^-; and administering the AT_4 receptor ligand.

31. (New) A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of: producing an AT_4 receptor ligand having a structure of: norleucine-tyrosine-leucine-Ψ-$(CH_2\text{-}NH_2)^{3\text{-}4}$-histidine-proline-phenylalanine-COO^-; and administering the AT_4 receptor ligand.